Cytokeratin, Acidic (Type I or LMW) (Epithelial Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone KRTL/1077 ]
|Application ||WB, IHC, IF, FC|
|Other Accession||374454, 334989|
|Isotype||Mouse / IgG1, kappa|
|Calculated MW||56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19)|
|Other Names||Keratin, type II cytoskeletal 1b, Cytokeratin-1B, CK-1B, Keratin-77, K77, Type-II keratin Kb39, KRT77, KRT1B|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Cytokeratin, Acidic (Type I or LMW) (Epithelial Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Expressed exclusively in skin.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This MAb recognizes the 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19) keratins of the acidic (Type I or LMW) subfamily. Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. The acidic keratins have molecular weights (MW) of 56.5, 55, 51, 50, 50 , 48, 46, 45, and 40kDa. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis.
Woodock-Mitchell J et. al. Journal of Cell Biology 1982;95:580-8. | Tseng SCG et. al. Cell 1982; 30361
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.